NLRP3 and oral lichen planus: Given that patients with OLP inherently present with comorbidities, and recognizing the differential expression of Gal-3 and NLRP3 in various immune-mediated diseases and inflammatory disorders, patients with alternative immune-mediated chronic inflammatory conditions were intentionally excluded to ensure sample homogeneity in this study.